John P. Gavin, CFA, is the founder and CEO of Disclosure Insight®, an independent publisher of investment research. Mr. Gavin has spent his entire career of over 25 years in the financial services industry. Prior to starting “DI” in 2000, he worked as an equity analyst and portfolio manager... More
BioPharma (NASDAQ: PDLI) announced this morning that CFO Christine Larson resigned last Friday and that it had initiated a search for her replacement. Larson’s unexpected departure takes the body count in the executive suite at PDLI to 4 CEOs, 3 CFOs (after a replacement is hired), and 5 principal accounting officers in the last 5 years.
In addition, there have been 12 departures from PDLI’s board, including 4 chairmen, over the same time period.
The lack of an immediate successor to the CFO is likely to create a significant amount of short-term discontinuity in the finance department while a replacement is identified. The company did not disclose who would assume Larson’s responsibilities while it conducted its search.
Notably, PDLI's stock has underperformed both the NASDAQ and NASDAQ Biotech Index (NBI) dating back to Dec-06 (NASDAQ: +6.4%, PDLI: +0.5%, NBI: +26.2%).
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha
community. Instablog posts are not selected, edited or screened by Seeking Alpha editors,
in contrast to contributors' articles.
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.
CFO's Abrupt Exit: One More Turn to the Revolving Door on PDLI's Executive Suite and Board 0 comments
BioPharma (NASDAQ: PDLI) announced this morning that CFO Christine Larson resigned last Friday and that it had initiated a search for her replacement. Larson’s unexpected departure takes the body count in the executive suite at PDLI to 4 CEOs, 3 CFOs (after a replacement is hired), and 5 principal accounting officers in the last 5 years.
In addition, there have been 12 departures from PDLI’s board, including 4 chairmen, over the same time period.
The lack of an immediate successor to the CFO is likely to create a significant amount of short-term discontinuity in the finance department while a replacement is identified. The company did not disclose who would assume Larson’s responsibilities while it conducted its search.
Notably, PDLI's stock has underperformed both the NASDAQ and NASDAQ Biotech Index (NBI) dating back to Dec-06 (NASDAQ: +6.4%, PDLI: +0.5%, NBI: +26.2%).
Here is a link to the Press Release.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
Share this page
Latest Followers
Latest Comments
Most Commented
Posts by Themes